Current Report Filing (8-k)
August 02 2016 - 4:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 2, 2016
Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50679
|
|
77-0487658
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
149 Commonwealth Drive
Menlo Park, CA 94025
(Address of principal executive offices, with zip code)
(650) 327-3270
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former, address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02. Results of Operations and Financial Condition
Item 7.01. Regulation FD Disclosure
On
August 2, 2016, Corcept Therapeutics Incorporated (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2016. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
The information in Item 2.02 and Item 7.01 and the information contained in the press release attached as Exhibit 99.1 shall not be
deemed filed for purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in Item 2.02
and Item 7.01 and the information contained in the press release attached as Exhibit 99.1 is not incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the
date hereof, regardless of any general incorporation language in the filing unless specifically stated so therein.
Item 9.01. Financial
Statements and Exhibits
(d) Exhibits
|
|
|
99.1
|
|
Press Release of Corcept Therapeutics Incorporated dated August 2, 2016
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
CORCEPT THERAPEUTICS INCORPORATED
|
|
|
By:
|
|
/s/ G. Charles Robb
|
|
|
Name: G. Charles Robb
|
|
|
Title: Chief Financial Officer and Secretary
|
Date: August 2, 2016
EXHIBIT INDEX
|
|
|
99.1
|
|
Press Release of Corcept Therapeutics Incorporated, dated August 2, 2016.
|
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Sep 2023 to Sep 2024